Abstract
Fibrosing mediastinitis is rare. One type of this disease is idiopathic fibrosing mediastinitis. It is necessary to rule out malignancy in order to accurately diagnose fibrosing mediastinitis. We herein report a case of anaplastic large cell lymphoma diagnosed three months after a preliminary diagnosis of fibrosing mediastinitis. Glucocorticoid therapy was not successful in controlling disease progression. Immediately after initiating chemotherapy for lymphoma, the patient's symptoms improved dramatically and the mediastinal lesion decreased in size. Although few similar cases have been reported, hidden malignancy may present as fibrosing mediastinitis. Therefore, physicians should consider the probability of malignancy in patients with fibrosing mediastinitis because treatments may vary accordingly.
MeSH terms
-
Adult
-
Anaplastic Lymphoma Kinase
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Bleomycin / administration & dosage
-
Cyclophosphamide / administration & dosage
-
Dacarbazine / administration & dosage
-
Diagnostic Errors
-
Doxorubicin / administration & dosage
-
Female
-
Fluorodeoxyglucose F18
-
Glucocorticoids / therapeutic use
-
Humans
-
Lymphoma, Large-Cell, Anaplastic / diagnosis*
-
Lymphoma, Large-Cell, Anaplastic / drug therapy
-
Mediastinitis / diagnosis*
-
Mediastinitis / drug therapy
-
Positron-Emission Tomography
-
Prednisone / administration & dosage
-
Radiopharmaceuticals
-
Receptor Protein-Tyrosine Kinases / metabolism
-
Sclerosis / diagnosis*
-
Sclerosis / drug therapy
-
Tomography, X-Ray Computed
-
Vinblastine / administration & dosage
-
Vincristine / administration & dosage
Substances
-
Glucocorticoids
-
Radiopharmaceuticals
-
Fluorodeoxyglucose F18
-
Bleomycin
-
Vincristine
-
Vinblastine
-
Dacarbazine
-
Doxorubicin
-
Cyclophosphamide
-
Anaplastic Lymphoma Kinase
-
Receptor Protein-Tyrosine Kinases
-
Prednisone
Supplementary concepts
-
ABVD protocol
-
CHOP protocol
-
Mediastinal Fibrosis